Insulin resistance in non-insulin-dependent diabetes is associated with a defective insulin activation ofthe enzyme glycogen synthase in skeletal muscles. To investigate whether this may be a primary defect, we studied 20 young (25±1 yr) Caucasian first-degree relatives (children) of patients with non-insulindependent diabetes, and 20 matched controls without a family history of diabetes. Relatives and controls had a normal oral glucose tolerance, and were studied by means of the euglycemic hyperinsulinemic clamp technique, which included performance of indirect calorimetry and muscle biopsies. Insulin-stimulated glucose disposal was decreased in the relatives (9.2±0.6 vs 11.5±0.5 mg/kg fat-free mass per (FFM) min, P < 0.02), and was due to a decreased rate of insulin-stimulated nonoxidative glucose metabolism (5.0±0.5 vs 7.5±0.4 mg/kg fat-free mass per min, P < 0.001). The insulin-stimulated, fractional glycogen synthase activity (0.1/10 mmol liter glucose-6-phosphate) was decreased in the relatives (46.9±2.3 vs 56.4±3.2%, P < 0.01), and there was a significant correlation between insulin-stimulated, fractional glycogen synthase activity and nonoxidative glucose metabolism in relatives (r = 0.76, P < 0.001) and controls (r = 0.63, P < 0.01). Furthermore, the insulin-stimulated increase in muscle glycogen content over basal values was lower in the relatives (13±25 vs 46±9 mmol/kg dry wt, P = 0.05). We conclude that the defect in insulin activation of muscle glycogen synthase may be a primary, possibly genetically determined, defect that contributes to the development of non-insulin-dependent diabetes. (J. Clin. Invest. 1992. 
Introduction
Decreased rates ofglucose disposal in response to a euglycemic, intravenous insulin infusion, defined as insulin resistance, may play an important role in the pathophysiology of non-insulin-dependent diabetes mellitus (NIDDM)' (1) (2) (3) (4) . The intracellular metabolic fate of glucose after passing the cell membrane is either through nonoxidative pathways, largely accounted for by storage of glucose as glycogen, or through oxidation of glucose in the Krebs cycle. The insulin resistance in NIDDM occurs in both oxidative and nonoxidative pathways, although the predominant defect is in nonoxidative glucose metabolism (3) (4) (5) (6) (7) (8) . The main site ofthe insulin resistance is considered to be in skeletal muscle (3, 5, 9) , and the reduced insulin-stimulated glucose disposal in NIDDM has been shown primarily to be due to decreased rates ofmuscle glucose storage as glycogen (9) . The rate limiting key enzyme in this pathway is glycogen synthase (10, 11) . Muscle glycogen synthase is dephosphorylated, and thus stimulated covalently by insulin (11, 12) , and a close correlation between in vivo insulin-stimulated muscle glycogen synthase activity, and whole body nonoxidative glucose disposal has been demonstrated in normal Caucasian subjects (4, 5, 11') , in Caucasian patients with NIDDM (4, 5) , and in a mixture of American Pima Indians with and without NIDDM (13) . In addition, a defect insulin activation of glycogen synthase in skeletal muscles has now become a well-established and consistent finding in NIDDM (4, 5, 14, 15) .
Recently, insulin resistance in the glucose storage pathway was demonstrated in obese "prediabetic" Pima Indians (16) , and in middle-aged obese Caucasian glucose tolerant, first-degree relatives of patients with NIDDM (17) . It was suggested that the insulin resistance could be a primary, and perhaps genetically determined, defect ofnonoxidative glucose metabolism that leads to the development ofNIDDM. In addition, the localization of this defect was inferred to be due to an impairment in activation by insulin of glycogen synthase in skeletal muscle (16, 17) . In these studies, however, no direct evidence for a defect of this pathway in skeletal muscle was provided. Furthermore, the possibility that the defect of nonoxidative glucose metabolism in the prediabetic Pima Indians and in the Caucasian relatives was due to obesity itself, cannot be excluded. Thus, we recently demonstrated that obesity in nondiabetic Caucasian subjects is associated with insulin resistance in the nonoxidative glucose metabolism, and furthermore, with a decreased insulin activation of glycogen synthase in skeletal muscle (4) .
Therefore, the aim of the present study was to measure in skeletal muscle the activation of glycogen synthase by insulin in nonobese, glucose-tolerant, Caucasian first-degree relatives ofpatients with NIDDM, a group known to be at risk for devel-oping NIDDM (18). Importantly, we elected to investigate relatives below the age of 30 yr, in order to establish whether a defect in nonoxidative glucose metabolism and/or in glycogen synthase activity in skeletal muscle is present several decades before a person is destined to develop NIDDM.
Methods

Subjects
Initially, 22 first-degree relatives (children) of patients with NIDDM were recruited to the study. These relatives were traced by questioning patients with verified NIDDM at the outpatient clinics at Hvid0re Hospital, and the Department of Endocrinology and Internal Medicine at Odense University Hospital. Subjects who fulfilled the inclusion criteria and who agreed to participate were included consecutively into the study. Inclusion criteria were the presence of at least two first-degree relatives with NIDDM, or alternatively, the presence ofone first-degree relative and at least two second-degree relatives with NIDDM. All relatives who participated in the study had at least one parent with verified NIDDM. Furthermore, only relatives between the age of 18 and 30 yr, and with normal oral glucose tolerance tests, were included in the study. Thus, two relatives were excluded from the study after performing the oral glucose tolerance test. One ofthese relatives had previously unrecognized NIDDM, and the other had impaired glucose tolerance. The 20 relatives who participated in the study were compared with 20 control subjects with normal oral glucose tolerance, and without any family history of NIDDM. Relatives and control subjects were carefully matched according to age, sex, and body mass index (Table I) . None of the subjects had clinical evidence of endocrine, cardiac, hepatic, or renal disease, and none ofthe subjects were taking any medication known to influence glucose metabolism. The subjects were not undertaking arduous exercise, and all subjects were instructed to avoid excessive physical exercise at least 2 d before clamp studies. All studies in relatives and controls were run in parallel to eliminate time and season variation in any of the measurements. Informed consent was obtained. The study was approved by the regional ethical committee, and the procedure was performed according to the principles of the Helsinki Declaration. (19) . After a 120-min basal equilibration period for basal measurements (Fig. 1 Indirect calorimetry. Indirect calorimetry was performed using a computerized, flowthrough canopy gas analyzer system (Deltatrac; Datex, Helsinki, Finland). Briefly, air was suctioned at a rate of40 liter per min through a canopy placed over the head of the subject. Samples of inspired and expired air were analyzed for oxygen concentration, using a paramagnetic differential oxygen sensor, and were analysed for carbon dioxide using an infrared carbon dioxide sensor. Signals from the gas analyzers were processed by the computer, and oxygen consumption, and carbon dioxide production was calculated and recorded once a minute. After an equilibration period of 10 min, the average gas exchange rates recorded over the two 30-min steady-state periods ( Fig.  1) were used to calculate rates ofglucose oxidation, lipid oxidation, and energy expenditure, as previously described (20, 21) . The protein oxidation rate was estimated from urinary urea nitrogen excretion (1 g nitrogen = 6.25 g protein) and corrected for changes in pool size (22) .
Muscle biopsy. Muscle biopsies were performed using a modified Bergstrom needle (including suction) under local anesthesia. The biopsies were rapidly (within 10-15 s) frozen, and stored in liquid nitrogen for later analysis. Before the biochemical analysis, the muscle samples were freeze dried and dissected free ofvisible connective tissue, fat, and blood.
Calculations. During the steady-state periods, glucose turnover rates (hepatic glucose output [HGO] and total peripheral glucose disposal) were calculated at 10-min intervals using Steele's equations (23) . In these calculations, the distribution volume of glucose was taken as 200 ml/kg body wt, and the pool fraction as 0.65 (24) . During the insulin infusion periods, negative rates of HGO were calculated in all subjects. Such underestimation of glucose turnover by the tracer method is largely accounted for by a model error emerging at high rates ofglucose metabolism (25 
Results
The relatives had normal fasting plasma glucose concentrations and normal levels of glycosylated hemoglobin, whereas fasting concentrations ofinsulin and C-peptide (mean values of four determinations) were significantly elevated (Table I) .
Plasma glucose and insulin concentrations during the oral glucose tolerance tests are given in Fig. 2 . Despite only marginally elevated plasma glucose concentrations in the relatives, insulin concentrations in these subjects were clearly elevated during the oral glucose tolerance test (net area under curve 47.4±6.8 vs 23.9±3.2 min nmol/liters, P < 0.005).
Plasma glucose, insulin, and NEFA concentrations during clamp studies are given in Table II . Plasma concentrations of glucose and insulin were constant during the predefined basal and insulin-stimulated steady-state periods, indicating that steady state was achieved during these two intervals. The mean coefficient of variation of plasma glucose concentrations during insulin infusions was 5% in both relatives and control studies. Plasma glucose concentrations were similar in relatives and control subjects during both basal and insulin-stimulated steady-state periods. Plasma insulin concentrations were elevated in the relatives in the basal state, but were similar during insulin infusion. Plasma NEFA concentrations were similar in Rates ofinsulin-stimulated glucose disposal were decreased in the relatives of patients with NIDDM (1 1.5±0.5 vs 9.2±0.6 mg/kg FFM per min, P < 0.02, Fig. 3) . Furthermore, the insulin sensitivity index was also significantly lower in Insulin-stimulated rates of glucose oxidation were similar in control subjects and relatives (4.0±0.2 vs 4.2±0.3 mg/kg FFM per min, NS), and thus the insulin resistance in the relatives was solely due to decreased rates of insulin-stimulated nonoxidative glucose disposal (7.5±0.4 vs 5.0±0.4 mg/kg FFM per min, P < 0.001).
In the basal state, rates of total peripheral glucose disposal The fractional skeletal muscle glycogen synthase activity at the physiological 0.1 mM G6P concentration (FV 0.1) was significantly decreased in the relatives during insulin infusion (Table III). In addition, the insulin-stimulated increments in fractional muscle glycogen synthase activities over basal values were significantly lower in the relatives compared to the controls, when measured both without G6P (FV 0.0), and in the presence ofthe physiological G6P concentration (FV 0.1), (Table III). Insulin-stimulated increments in fractional glycogen synthase activities at 0.1 mmol/liter G6P (FV 0.1) correlated significantly with insulin-stimulated increments in whole body nonoxidative glucose metabolism, in both controls and relatives (r = 0.63, P < 0.005 and r = 0.76, P < 0.0005, respectively, Fig. 4 ).
The insulin-stimulated increase in muscle glycogen content over basal values was significantly lower in the relatives (Table  IV) . Intracellular concentrations of free glucose and G6P were unchanged in both groups during insulin infusion, and were similar in control subjects and relatives (Table IV) .
Discussion
The present study demonstrates that insulin resistance is present in young nonobese Caucasian persons with a known increased risk for developing NIDDM decades before they are believed to contract the disease. The insulin resistance is located in the nonoxidative glucose metabolic pathway, and is closely correlated with a defect in insulin activation of muscle glycogen synthase. The decreased storage of glucose as muscle glycogen in response to the physiological insulin infusion provides further and direct evidence for a defect in this pathway in the first-degree relatives of patients with NIDDM. (43) . Longitudinal studies in Pima indians (16) and in rhesus monkeys (44) have demonstrated that insulin resistance precedes the development of MDDM. In addition, the recent prospective study of children of two diabetic parents demonstrated that a slow glucose-removal rate was associated with hyperinsulinemia, implying insulin resistance, and preceded the development ofNIDDM in these subjects ( 18). Insulin resistance in the nonoxidative pathway has been demonstrated in obese prediabetic Pima Indians (16), in obese and middle-aged, glucose-tolerant, Caucasian first-degree relatives of patients with NIDDM (17), and was demonstrated in the present study in young and carefully weight and sex matched nonobese glucose-tolerant Caucasian first-degree relatives of patients with NIDDM. Thus, these data taken together indicate that a familiarly and perhaps genetically determined insulin resistance in the glucose storage pathway may precede the development of frank NIDDM, and thus may be involved in causing the disease. Importantly, we demonstrated in the present study that the biochemical defect responsible for the defect of insulin action in these young Caucasian relatives with increased risk for development of NIDDM was a defect of insulin activation of the enzyme glycogen synthase in skeletal muscle, which was furthermore associated with a decreased increment in skeletal muscle glycogen content in response to the physiological insu- lin infusion. Therefore, the defective insulin activation of glycogen synthase may also be an inherited defect involved in the emergence of NIDDM.
Patients with overt NIDDM often have elevated fasting and postprandial plasma nonesterified fatty acid concentrations (45, 46) . Through operation ofthe glucose-fatty acid cycle (47) , it has been suggested that the impaired glucose utilization (insulin resistance) in NIDDM may be secondary to an enhanced rate ofoxidation oflipids (48) . In support ofthis hypothesis, we recently demonstrated that acute administration of the antilipolytic nicotinic acid analogue Acipimox improved the insulin action in NIDDM 30% by improving both the insulin-stimulated oxidative and nonoxidative glucose metabolism (49) . The normal basal and insulin-stimulated NEFA levels, and the lipid oxidation rates observed in the relatives in the present study, are in accordance with the findings of Eriksson et al. in obese relatives (17) , indicating that the insulin resistance in the relatives ofpatients with NIDDM may not be secondary to any abnormalities in the lipid metabolism. This may also suggest that the insulin resistance in overt NIDDM, apart from having a "metabolic" component secondary to an enhanced lipid oxidation, may have a primary, and perhaps genetically determined, component. We previously found that insulin was unable to significantly stimulate the activity of muscle glycogen synthase in newly presenting obese patients with NIDDM (4). Given the fact that insulin was able to stimulate the activity of glycogen synthase in all but one ofthe relatives (Fig. 4) , and furthermore, that there was considerable overlap of the insulin-stimulated nonoxidative glucose metabolism and activation of glycogen synthase between the groups ofrelatives and controls (Fig. 4) , it may seem unlikely that the degree of defect in insulin action and in glycogen synthase activation demonstrated in the relatives in this study is by itself sufficient to cause frank NIDDM. Therefore, other (secondary?) factors such as elevated plasma NEFA concentrations and/or obesity (4) may be involved in further unmasking the defect in activation ofglycogen synthase in the group who develops NIDDM, thereby clearly separating this group from the group who will escape development of NIDDM. Alternatively, the implication of the considerable overlap in insulin action and in the activation in glycogen synthase activity between the groups could be that, in addition to the familiarly determined defect in insulin action, a certain degree ofa (genetically determined ?) defect in insulin secretion may be required for the development of frank NIDDM.
The present study does not answer the question ofwhether the defect glycogen synthase activation in the relatives is due to a defect in the enzyme per se, or whether it may be secondary to, and the effect of, other potential defects in the cellular insulin signal transduction before the activation of glycogen synthase. The molecular mechanism by which insulin stimulates glycogen synthase is complicated and not fully understood (50) . Initially, insulin binds to the receptor (alpha subunit) on the cell membrane surface. The transmembrane part of the receptor (beta subunit) is a tyrosine kinase (insulin receptor tyrosine kinase), which after insulin stimulation is autophosphorylated, and may initiate a cascade of phosphorylation-dephosphorylation reactions of other proteins. Eventually, this cascade reaction produces phosphorylation, and subsequently, activation of the specific glycogen synthase phosphatase (protein phosphatase one or PP 1) that is responsible for the dephosphorylation and activation of glycogen synthase (50) . A defect in in vivo insulin activation of the insulin receptor tyrosine kinase in skeletal muscles was recently reported in Pima Indians with NIDDM (51), indicating that this could explain some of the insulin resistance in this syndrome. On the other hand, the same study indicated that the site of insulin resistance in nondiabetic Pima Indians was located distal to the tyrosine kinase (51) . Furthermore, it has been demonstrated that the defect tyrosine kinase activity in adipocytes from NIDDM patients can be completely reversed after intensive hypocaloric treatment (52) . Thus, a defect insulin receptor kinase activity may not explain the defect insulin stimulation of muscle glycogen synthase activity in the nondiabetic relatives in this study. However, other defects in the insulin signal system could have caused the defect, as for example, reduced rates of glycogen synthase phosphatase activities (53) , and/or a defective insulin-induced inhibition of cAMP-dependent protein kinase in skeletal muscle (54) . Finally, abnormalities in inositol metabolism (55) or in as yet unidentified insulin signal transduction systems could theoretically contribute to the observed impairment of glycogen synthase activation in the relatives.
Despite insulin resistance, the relatives in the present study had normal fasting plasma glucose concentrations, normal levels of glycosylated hemoglobin, and only marginally elevated plasma glucose concentrations during the oral glucose tolerance tests. This can be explained by the compensatory hypersecretion of insulin from the pancreatic beta-cell in the relatives, enabling these subjects to overcome the insulin resistance. In fact, hyperinsulinemia has previously been demonstrated in nondiabetic relatives to NIDDM patients in the fasting state ( 18, 56, 57), after an oral glucose load (56, 57) , after an intravenous glucose infusion (second phase insulin response) (18), and was demonstrated in the relatives in the present study both in the fasting state and in response to an oral glucose load. The finding of hyperinsulinemia, in spite ofnormal plasma glucose concentrations, also indicates normal beta-cell function in the relatives, which suggests that the defect insulin secretion in NIDDM (58) is not an early (primary) defect.
In conclusion, our study demonstrates that insulin resistance is present in young and carefully sex and weight matched nonobese Caucasian first-degree relatives of patients with NIDDM, decades before these subjects may develop frank diabetes. The insulin resistance is located to the glucose storage pathway, and is probably due to an impaired activation of the enzyme glycogen synthase in skeletal muscles. This defect could be a primary, and perhaps genetically determined, defect that contributes to the development of non-insulin-dependent diabetes mellitus.
